Author

Yuanyuan Kong

Observed name: Y. Kong

Institution: Gaochun People's Hospital

Observed institutions: Capital Medical University, Gaochun People's Hospital, Second Affiliated Hospital of Soochow University, Beijing Obstetrics and Gynecology Hospital

ORCID: 0009-0008-2407-5951

Observed ORCID: 0009-0008-2407-5951

OpenAlex ID: A5041194161

Neonatal Amino Acids and Acylcarnitines Associated With Maternal Blood Glucose Levels Throughout Pregnancy: Insights From the Beijing Birth Cohort Study

2024 · Wei Zheng, Xianxian Yuan, et al. · Diabetes Care · 10

The Prognostic and Early Efficacy Prediction Value of Baseline C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index in Advanced Pancreatic Cancer

2025 · Liangxue Zhu, Yuanyuan Kong, et al. · International Journal of General Medicine · 8

PO-2211 Early data of a phase II study of PRaG3.0 regimen for remedy of HER2-expressing advanced pan-cancer

2023 · M. Xu, R. Chen, et al. · Radiotherapy and Oncology · 1

PD-1 Inhibitor Combined with Radiotherapy and GM-CSF with or not IL-2 (PRaG regimen) in Patients with Microsatellite Stable Metastatic Colorectal Cancer

2022 · J. Yang, P. Xing, et al. · International Journal of Radiation Oncology*Biology*Physics · 1

Warm autoimmune hemolytic anemia following definitive chemoradiotherapy for cervical cancer: A case report

2026 · Yuanyuan Kong, Liangxue Zhu, et al. · Oncology Letters

Author response for "Identification of growth differentiation factor 15 as an early predictive biomarker for metabolic dysfunction‐associated steatohepatitis: A nested case–control study of UK Biobank proteomic data"

2025 · Hao Wang, Xiaoqian Xu, et al. · Publons reviews and discussion

PD-1 Inhibitors Combined with Radiotherapy and GM-CSF, Sequentially Followed by IL-2 (PRaG 2.0) Regimen in Metastatic Tumors: A Prospective, Multicenter, Single-Arm Clinical Trial

2022 · P. Xing, J. Yang, et al. · International Journal of Radiation Oncology*Biology*Physics

Works count: 7

Citation count: 20

H-index: 2

I10-index: 1